Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5298710 | 0.86 | DRD2 (0.39) | CHRNA7ALDH1A1GAAMAPTDRD2 | |
| SCHEMBL5305210 | 0.86 | CYP1A2 (0.36) | CHRNA7ALDH1A1MAPTDRD2SIGMAR1 | |
| SCHEMBL5287524 | 0.84 | CES2 (0.36) | CHRNA7CES2ELANEGAA | |
| SCHEMBL5301648 | 0.83 | SMN1; SMN2 (0.37) | KDM4EALDH1A1ELANEGAAMAPT | |
| SCHEMBL5288405 | 0.83 | GRM2 (0.38) | CHRNA7KDM4EALDH1A1ELANEGAA | |
| SCHEMBL5302904 | 0.82 | KCNH2 (0.35) | KDM4EALDH1A1GAAMAPTALOX12 | |
| SCHEMBL5288822 | 0.82 | GRM2 (0.40) | KDM4EALDH1A1ELANEGAAMAPT | |
| SCHEMBL5305591 | 0.80 | KCNH2 (0.38) | KDM4EALDH1A1GAAMAPTALOX12 | |
| SCHEMBL5304308 | 0.80 | KCNH2 (0.38) | KDM4EALDH1A1GAAMAPTALOX12 | |
| SCHEMBL5810268 | 0.80 | KCNH2 (0.38) | KDM4EALDH1A1GAAMAPTALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100321863-A1 | ACTIVATED CARBON AND PROCESS FOR PRODUCING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-12-23 | — | — | US | disclosed |
| US-7785495-B2 | Activated carbon prepared by carbonizing and activating a calixarene containing dihydroxybenzene rings; especially calcining at 400 degrees C. or less in the presence of an oxidative gas, calcining at 1500 degrees or less in an inactive gas, and then further calcining at 200-1500 degrees in H2O or CO2 | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-08-31 | — | — | US | disclosed |
| EP-2093191-A1 | ACTIVATED CARBON AND METHOD FOR PRODUCING THE SAME | Sumitomo Chemical Company, Limited (JP) | 2009-08-26 | — | — | EP | disclosed |
| US-20090103241-A1 | Activated carbon prepared by carbonizing and activating a calixarene containing dihydroxybenzene rings; especially calcining at 400 degrees C. or less in the presence of an oxidative gas, calcining at 1500 degrees or less in an inactive gas, and then further calcining at 200-1500 degrees in H2O or CO2 | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1905740-A1 | ELECTRIC DOUBLE LAYER CAPACITOR | Sumitomo Chemical Company, Limited (JP) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007006418-A1 | IONIC-LIQUID-CONTAINING PRODUCTS FOR DYEING AND/OR BRIGHTENING KERATIN FIBRES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006131234-A1 | COSMETIC COMPOSITIONS COMPRISING IONIC LIQUIDS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090103241-A1 | Activated carbon prepared by carbonizing and activating a calixarene containing dihydroxybenzene rings; especially calcining at 400 degrees C. or less in the presence of an oxidative gas, calcining at 1500 degrees or less in an inactive gas, and then further calcining at 200-1500 degrees in H2O or CO2 | CBR1, CYP24A1, CALU | CHRNA7 1263/4885ALOX5 243/4885CES2 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.